SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-006094 to Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260) (FBIO)

Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)
Date: May 24, 2024 · CIK: 0001429260 · Accession: 0000000000-24-006094

AI Filing Summary & Sentiment

File numbers found in text: 333-279516

Date
May 24, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)

Letter

United States securities and exchange commission logo May 24, 2024 Lindsay Rosenwald Chief Executive Officer Fortress Biotech, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 Re:Fortress Biotech, Inc. Registration Statement on Form S-3 Filed May 17, 2024 File No. 333-279516 Dear Lindsay Rosenwald: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Wolpa

Show Raw Text
United States securities and exchange commission logo
May 24, 2024
Lindsay Rosenwald
Chief Executive Officer
Fortress Biotech, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, FL 33154
Re:Fortress Biotech, Inc.
Registration Statement on Form S-3
Filed May 17, 2024
File No. 333-279516
Dear Lindsay Rosenwald:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       David Wolpa